Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with multiple sclerosis, showing no higher risk for poor COVID-19 outcomes in these patients. Objective: In this multicenter study, we aimed to evaluate COVID-19 clinical outcomes in pregnant patients with multiple sclerosis. Methods: We recruited 85 pregnant patients with multiple sclerosis who contracted COVID-19 after conception and were prospectively followed-up in Italian and Turkish Centers, in the period 2020-2022. A control group of 1354 women was extracted from the database of the Multiple Sclerosis and COVID-19 (MuSC-19). Univariate and subsequent logistic regression models were fitted to search for risk factors associated with severe COVID-19 course (at least one outcome among hospitalization, intensive care unit [ICU] admission and death). Results: In the multivariable analysis, independent predictors of severe COVID-19 were age, body mass index ⩾ 30, treatment with anti-CD20 and recent use of methylprednisolone. Vaccination before infection was a protective factor. Vaccination before infection was a protective factor. Pregnancy was not a risk nor a protective factor for severe COVID-19 course. Conclusion: Our data show no significant increase of severe COVID-19 outcomes in patients with multiple sclerosis who contracted the infection during pregnancy.

Sars-CoV2 infection in pregnant women with multiple sclerosis / Aprea, Maria Grazia; Schiavetti, Irene; Portaccio, Emilio; Ballerini, Chiara; Battaglia, Mario Alberto; Bergamaschi, Roberto; Brichetto, Giampaolo; Bunul, S Destan; Calabrese, Massimiliano; Capobianco, Marco; Cavalla, Paola; Celani, Maria Grazia; Clerico, Marinella; Cocco, Eleonora; Comi, Giancarlo; Confalonieri, Paolo; Conte, Antonella; Cordioli, Cinzia; De Luca, Giovanna; De Rossi, Nicola; Filippi, Massimo; Gumes, Haluk; Immovilli, Paolo; Inglese, Matilde; Karabudak, Rana; Landi, Doriana; Lanzillo, Roberta; L'Episcopo, Maria Rita; Lorefice, Lorena; Mantero, Vittorio; Marangoni, Sabrina; Marfia, Girolama Alessandra; Masciulli, Camilla; Milano, Eva; Moiola, Lucia; Orlandi, Riccardo; Patti, Francesco; Perini, Paola; Pesci, Ilaria; Pucci, Eugenio; Puthenparampil, Marco; Radaelli, Marta; Salvetti, Marco; Sartori, Arianna; Scandellari, Cinzia; Sen, Sedat; Siva, Aksel; Strumia, Silvia; Teatini, Francesco; Tedeschi, Gioacchino; Trojano, Maria; Tutuncu, Melih; Vaula, Giovanna; Sormani, Maria Pia; Amato, Maria Pia. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - (2023), p. 13524585231176174. [10.1177/13524585231176174]

Sars-CoV2 infection in pregnant women with multiple sclerosis

Ballerini, Chiara;Conte, Antonella;Patti, Francesco;Pucci, Eugenio;Salvetti, Marco;Sormani, Maria Pia;
2023

Abstract

Background: In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with multiple sclerosis, showing no higher risk for poor COVID-19 outcomes in these patients. Objective: In this multicenter study, we aimed to evaluate COVID-19 clinical outcomes in pregnant patients with multiple sclerosis. Methods: We recruited 85 pregnant patients with multiple sclerosis who contracted COVID-19 after conception and were prospectively followed-up in Italian and Turkish Centers, in the period 2020-2022. A control group of 1354 women was extracted from the database of the Multiple Sclerosis and COVID-19 (MuSC-19). Univariate and subsequent logistic regression models were fitted to search for risk factors associated with severe COVID-19 course (at least one outcome among hospitalization, intensive care unit [ICU] admission and death). Results: In the multivariable analysis, independent predictors of severe COVID-19 were age, body mass index ⩾ 30, treatment with anti-CD20 and recent use of methylprednisolone. Vaccination before infection was a protective factor. Vaccination before infection was a protective factor. Pregnancy was not a risk nor a protective factor for severe COVID-19 course. Conclusion: Our data show no significant increase of severe COVID-19 outcomes in patients with multiple sclerosis who contracted the infection during pregnancy.
2023
COVID-19; COVID-19 outcomes; Multiple sclerosis; SARS-CoV-2 infection; pregnancy; risk factors
01 Pubblicazione su rivista::01a Articolo in rivista
Sars-CoV2 infection in pregnant women with multiple sclerosis / Aprea, Maria Grazia; Schiavetti, Irene; Portaccio, Emilio; Ballerini, Chiara; Battaglia, Mario Alberto; Bergamaschi, Roberto; Brichetto, Giampaolo; Bunul, S Destan; Calabrese, Massimiliano; Capobianco, Marco; Cavalla, Paola; Celani, Maria Grazia; Clerico, Marinella; Cocco, Eleonora; Comi, Giancarlo; Confalonieri, Paolo; Conte, Antonella; Cordioli, Cinzia; De Luca, Giovanna; De Rossi, Nicola; Filippi, Massimo; Gumes, Haluk; Immovilli, Paolo; Inglese, Matilde; Karabudak, Rana; Landi, Doriana; Lanzillo, Roberta; L'Episcopo, Maria Rita; Lorefice, Lorena; Mantero, Vittorio; Marangoni, Sabrina; Marfia, Girolama Alessandra; Masciulli, Camilla; Milano, Eva; Moiola, Lucia; Orlandi, Riccardo; Patti, Francesco; Perini, Paola; Pesci, Ilaria; Pucci, Eugenio; Puthenparampil, Marco; Radaelli, Marta; Salvetti, Marco; Sartori, Arianna; Scandellari, Cinzia; Sen, Sedat; Siva, Aksel; Strumia, Silvia; Teatini, Francesco; Tedeschi, Gioacchino; Trojano, Maria; Tutuncu, Melih; Vaula, Giovanna; Sormani, Maria Pia; Amato, Maria Pia. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - (2023), p. 13524585231176174. [10.1177/13524585231176174]
File allegati a questo prodotto
File Dimensione Formato  
10.1177_13524585231176174.pdf

accesso aperto

Note: Aprea_Sars-CoV2 infection in pregnant women_2023
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1683376
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact